268 related articles for article (PubMed ID: 7809209)
1. In vitro synergism of concentrated Allium sativum extract and amphotericin B against Cryptococcus neoformans.
Davis LE; Shen J; Royer RE
Planta Med; 1994 Dec; 60(6):546-9. PubMed ID: 7809209
[TBL] [Abstract][Full Text] [Related]
2. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans.
Shen J; Davis LE; Wallace JM; Cai Y; Lawson LD
Planta Med; 1996 Oct; 62(5):415-8. PubMed ID: 8923805
[TBL] [Abstract][Full Text] [Related]
3. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Khyriem AB; Sujatha S; Parija SC
Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
[TBL] [Abstract][Full Text] [Related]
4. In vitro effect of aqueous extract of garlic (Allium sativum) on the growth and viability of Cryptococcus neoformans.
Fromtling RA; Bulmer GS
Mycologia; 1978; 70(2):397-405. PubMed ID: 353553
[No Abstract] [Full Text] [Related]
5. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans.
Barchiesi F; Giacometti A; Cirioni O; Arzeni D; Silvestri C; Kamysz W; Abbruzzetti A; Riva A; Kamysz E; Scalise G
Peptides; 2007 Aug; 28(8):1509-13. PubMed ID: 17698253
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis.
Wang H; Xu K; Liu L; Tan JP; Chen Y; Li Y; Fan W; Wei Z; Sheng J; Yang YY; Li L
Biomaterials; 2010 Apr; 31(10):2874-81. PubMed ID: 20044131
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
11. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
[TBL] [Abstract][Full Text] [Related]
12. Anti-cryptococcal activity of ethanol crude extract and hexane fraction from Ocimum basilicum var. Maria bonita: mechanisms of action and synergism with amphotericin B and Ocimum basilicum essential oil.
Cardoso NN; Alviano CS; Blank AF; Arrigoni-Blank MF; Romanos MT; Cunha MM; da Silva AJ; Alviano DS
Pharm Biol; 2017 Dec; 55(1):1380-1388. PubMed ID: 28317465
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome.
Poon M; Cronin DC; Wormser GP; Bottone EJ
Arch Pathol Lab Med; 1988 Feb; 112(2):161-2. PubMed ID: 3276290
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole.
Wei GX; Bobek LA
J Antimicrob Chemother; 2004 May; 53(5):750-8. PubMed ID: 15073161
[TBL] [Abstract][Full Text] [Related]
16. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y
J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
[TBL] [Abstract][Full Text] [Related]
17. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
18. In vitro virucidal effects of Allium sativum (garlic) extract and compounds.
Weber ND; Andersen DO; North JA; Murray BK; Lawson LD; Hughes BG
Planta Med; 1992 Oct; 58(5):417-23. PubMed ID: 1470664
[TBL] [Abstract][Full Text] [Related]
19. In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii.
Rossato L; Loreto ÉS; Zanette RA; Chassot F; Santurio JM; Alves SH
Folia Microbiol (Praha); 2016 Sep; 61(5):399-403. PubMed ID: 26847460
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis.
Joseph-Horne T; Loeffler RS; Hollomon DW; Kelly SL
J Med Vet Mycol; 1996; 34(3):223-5. PubMed ID: 8803806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
